{"resourceType": "EvidenceVariable", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "urn:ietf:rfc:3986", "value": "https://fevir.net/FOI/236974", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-313963", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "outcomeId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "313963"}, {"type": {"text": "picoId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "85798"}, {"type": {"text": "sectionId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "73215"}], "name": "Serious_hyperglycaemia313963", "title": "OutcomeDefinition: Serious hyperglycaemia", "shortTitle": "Serious hyperglycaemia", "status": "active", "description": "Serious hyperglycaemia", "author": [{"name": "Computable Publishing\u00ae: MAGIC-to-FEvIR Converter"}], "definition": {"concept": {"text": "Serious hyperglycaemia"}}, "handling": "dichotomous", "meta": {"versionId": "63", "lastUpdated": "2025-03-15T18:13:51.413Z"}, "url": "https://fevir.net/resources/EvidenceVariable/236974", "id": "236974", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "extension": [{"extension": [{"url": "type", "valueCode": "part-of"}, {"url": "targetReference", "valueReference": {"type": "Composition", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-conversion-report", "assigner": {"display": "Computable Publishing LLC"}}, "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"}}], "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/relates-to"}]}